CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-03 | Heerma Peter Chief Commercial Officer | Sale | −3,091 | $8.25 | $26K | 80,257 |
| 2023-09-05 | Cline Christopher R. Chief Financial Officer | Sale | −457 | $14.71 | $7K | 50,574 |
| 2023-09-05 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,815 | $14.71 | $27K | 61,173 |
| 2023-09-05 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −1,815 | $14.71 | $27K | 58,096 |
| 2023-09-05 | Dube Eric M Chief Executive Officer | Sale | −4,455 | $14.71 | $66K | 242,595 |
| 2023-08-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +3,300 | 62,988 | ||
| 2023-08-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +3,300 | 59,911 | ||
| 2023-08-31 | Dube Eric M Chief Executive Officer | Grant or award | +9,900 | 247,050 | ||
| 2023-05-17 | Baynes Roy D. Director | Grant or award | +4,500 | 24,500 | ||
| 2023-05-17 | Baynes Roy D. Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | Poole Sandra Director | Grant or award | +4,500 | 17,000 | ||
| 2023-05-17 | Poole Sandra Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | Williams Brinkley Ruth Director | Grant or award | +4,500 | 12,750 | ||
| 2023-05-17 | Williams Brinkley Ruth Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | Meckler Jeffrey A Director | Grant or award | +4,500 | 74,500 | ||
| 2023-05-17 | Meckler Jeffrey A Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | LYONS GARY A Director | Grant or award | +4,500 | 44,500 | ||
| 2023-05-17 | LYONS GARY A Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | COUGHLIN TIMOTHY Director | Grant or award | +4,500 | 42,500 | ||
| 2023-05-17 | COUGHLIN TIMOTHY Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 |
Page 26 of 51 · 1,020 trades